ES2865412T3 - Inhibidores de beta-hidrolasa para tratamiento del cáncer - Google Patents
Inhibidores de beta-hidrolasa para tratamiento del cáncer Download PDFInfo
- Publication number
- ES2865412T3 ES2865412T3 ES17202827T ES17202827T ES2865412T3 ES 2865412 T3 ES2865412 T3 ES 2865412T3 ES 17202827 T ES17202827 T ES 17202827T ES 17202827 T ES17202827 T ES 17202827T ES 2865412 T3 ES2865412 T3 ES 2865412T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- hydroxy
- acetoxy
- furanyl
- furanon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *OC*C(N*OC(C1=O)=C(N)OC1I)=C Chemical compound *OC*C(N*OC(C1=O)=C(N)OC1I)=C 0.000 description 2
- VPKIUOQJQJVLRW-UHFFFAOYSA-N CC(C1=O)OC(C)=C1OC(C)=O Chemical compound CC(C1=O)OC(C)=C1OC(C)=O VPKIUOQJQJVLRW-UHFFFAOYSA-N 0.000 description 1
- KCTDPHLBVROVQA-UHFFFAOYSA-N Cc([o]c(N=C)c1OC)c1[O](C)=C Chemical compound Cc([o]c(N=C)c1OC)c1[O](C)=C KCTDPHLBVROVQA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/66—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261704014P | 2012-09-21 | 2012-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2865412T3 true ES2865412T3 (es) | 2021-10-15 |
Family
ID=50342080
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17202827T Active ES2865412T3 (es) | 2012-09-21 | 2013-09-20 | Inhibidores de beta-hidrolasa para tratamiento del cáncer |
| ES13838498.7T Active ES2660822T3 (es) | 2012-09-21 | 2013-09-20 | Inhibidores de beta-hidrolasa para tratamiento del cáncer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13838498.7T Active ES2660822T3 (es) | 2012-09-21 | 2013-09-20 | Inhibidores de beta-hidrolasa para tratamiento del cáncer |
Country Status (10)
| Country | Link |
|---|---|
| US (8) | US9771356B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3345596B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6469009B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102137180B1 (cg-RX-API-DMAC10.html) |
| CN (2) | CN110818660B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2013317791B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2885762C (cg-RX-API-DMAC10.html) |
| ES (2) | ES2865412T3 (cg-RX-API-DMAC10.html) |
| HK (1) | HK1208805A1 (cg-RX-API-DMAC10.html) |
| WO (2) | WO2014047519A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3345596B1 (en) | 2012-09-21 | 2021-01-20 | Rhode Island Hospital | Inhibitors of beta-hydrolase for treatment of cancer |
| WO2019012159A1 (en) * | 2017-07-14 | 2019-01-17 | Protea Biopharma N.V. | METHODS AND MEANS FOR DIAGNOSING AND / OR TREATING A FATIGUE-ASSOCIATED DISEASE |
| WO2019246093A1 (en) * | 2018-06-18 | 2019-12-26 | Midwestern University | Monoclonal antibodies targeting epitopes of asph |
| CN109364251A (zh) * | 2018-12-06 | 2019-02-22 | 苏州大学 | Tet蛋白在治疗抑郁症中的应用 |
| KR20210129115A (ko) * | 2019-02-15 | 2021-10-27 | 미드웨스턴 유니버시티 | 동위원소-안정화된 테트론이미드 화합물 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE39717C (de) | H. LEHMANN in München, Enhuberstr. 5 part | Bleistifthalter | ||
| DD39717A (cg-RX-API-DMAC10.html) * | ||||
| JPS63500375A (ja) * | 1985-08-02 | 1988-02-12 | シエブロン リサ−チ カンパニ− | 除草性２−（オクサまたはチアヘテロサイクル）５−アミノ−３−オクソ−４−（置換−フェニル）−２、３−ジヒドロフラン類 |
| US5314913A (en) * | 1992-12-08 | 1994-05-24 | American Home Products Corporation | 4- or 5-(substituted sulfonyl)methyl-3(2H)-furanones |
| US5698585A (en) * | 1995-04-13 | 1997-12-16 | Kikkoman Corporation | Pharmaceutical preparation for prevention and/or treatment for cataract |
| JPH09110853A (ja) * | 1995-10-12 | 1997-04-28 | Kikkoman Corp | ４‐アシルオキシフラノン誘導体又はその塩及びその製造方法 |
| UA57002C2 (uk) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
| WO1998041516A1 (en) | 1997-03-14 | 1998-09-24 | Merck Frosst Canada & Co. | (methylsulfonyl)phenyl-2-(5h)-furanones with oxygen link as cox-2 inhibitors |
| US5877193A (en) * | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
| TW528755B (en) * | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
| US6835370B2 (en) | 1999-11-08 | 2004-12-28 | Rhode Island Hospital | Diagnosis and treatment of malignant neoplasms |
| US20050123545A1 (en) | 1999-11-08 | 2005-06-09 | Wands Jack R. | Diagnosis and treatment of malignant neoplasms |
| US20030031670A1 (en) | 1999-11-08 | 2003-02-13 | Jack R. Wands | Diagnosis and treatment of malignant neoplasms |
| WO2003018575A1 (en) * | 2001-08-24 | 2003-03-06 | Wyeth Holdings Corporation | 5-substituted-3(2h)-furanones useful for inhibition of farnesyl-protein transferase |
| US6667330B2 (en) * | 2002-01-31 | 2003-12-23 | Galileo Pharmaceuticals, Inc. | Furanone derivatives |
| AU2002950862A0 (en) | 2002-08-19 | 2002-09-12 | Biosignal Pty Ltd | Furanone derivatives and methods of making same |
| EP1554394B1 (en) | 2002-10-16 | 2009-12-16 | Isis Innovation Limited | Screening methods using a structural model of FIH |
| WO2005070916A1 (en) * | 2004-01-09 | 2005-08-04 | Eli Lilly And Company | Thiophene and furan compounds |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| EP2576532B1 (en) * | 2010-06-07 | 2018-07-18 | Novomedix, LLC | Furanyl compounds and the use thereof |
| EP3345596B1 (en) | 2012-09-21 | 2021-01-20 | Rhode Island Hospital | Inhibitors of beta-hydrolase for treatment of cancer |
-
2013
- 2013-09-20 EP EP17202827.6A patent/EP3345596B1/en not_active Not-in-force
- 2013-09-20 EP EP13838498.7A patent/EP2897607B1/en not_active Not-in-force
- 2013-09-20 ES ES17202827T patent/ES2865412T3/es active Active
- 2013-09-20 HK HK15109523.0A patent/HK1208805A1/xx unknown
- 2013-09-20 CN CN201910949656.0A patent/CN110818660B/zh not_active Expired - Fee Related
- 2013-09-20 WO PCT/US2013/061050 patent/WO2014047519A2/en not_active Ceased
- 2013-09-20 AU AU2013317791A patent/AU2013317791B2/en not_active Ceased
- 2013-09-20 WO PCT/US2013/060934 patent/WO2014047447A2/en not_active Ceased
- 2013-09-20 ES ES13838498.7T patent/ES2660822T3/es active Active
- 2013-09-20 CN CN201380061004.4A patent/CN104902889A/zh active Pending
- 2013-09-20 JP JP2015533237A patent/JP6469009B2/ja not_active Expired - Fee Related
- 2013-09-20 KR KR1020157010188A patent/KR102137180B1/ko not_active Expired - Fee Related
- 2013-09-20 US US14/430,101 patent/US9771356B2/en active Active
- 2013-09-20 CA CA2885762A patent/CA2885762C/en active Active
-
2017
- 2017-07-17 US US15/651,842 patent/US10106532B2/en active Active
- 2017-09-26 US US15/715,989 patent/US10710995B2/en active Active
-
2018
- 2018-09-14 US US16/131,275 patent/US10351555B2/en active Active
-
2019
- 2019-06-12 US US16/439,253 patent/US10787445B2/en active Active
-
2020
- 2020-06-02 US US16/890,680 patent/US20200361925A1/en not_active Abandoned
- 2020-09-23 US US17/029,127 patent/US20210032233A1/en not_active Abandoned
-
2022
- 2022-04-14 US US17/720,472 patent/US20220251076A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220251076A1 (en) | Inhibitors of Beta-Hydoxylase for Treatment of Cancer | |
| JP5941173B2 (ja) | ＩＲＥ−１αインヒビター | |
| ES2620634T3 (es) | Activadores de piruvato quinasa humana | |
| BR112016018371B1 (pt) | Derivados de indolona substituídos com pirrol, composição os compreendendo e uso dos mesmos | |
| CA3143196A1 (en) | Acetyl-coa synthetase 2 (acss2) inhibitors and methods using same | |
| KR102384381B1 (ko) | 헥사하이드로디벤조[a,g]퀴놀리진계 화합물의 약물 용도 | |
| US10961211B2 (en) | Isotopically-stabilized tetronimide compounds | |
| US20210052561A1 (en) | Targeting aspartate beta-hydroxylase suppresses tumor malignancy and metastasis | |
| WO2023076567A1 (en) | Lox enzyme inhibiting methods and compositions |